

14. Curran M, et al. Tadalafil. *Drugs*. 2003;63:2203.
15. Bella AJ, et al. Tadalafil in the treatment of erectile dysfunction. *Curr Urol Rep*. 2003;4:472.
16. Zhou Z, et al. Meta-Analysis of the Long-Term Efficacy and Tolerance of Tadalafil Daily Compared With Tadalafil On-Demand in Treating Men With Erectile Dysfunction. *Sexual medicine*. 2019;7:282.
17. Paduch DA, et al. Effects of 12 weeks of tadalafil treatment on ejaculatory and orgasmic dysfunction and sexual satisfaction in patients with mild to severe erectile dysfunction: integrated analysis of 17 placebo-controlled studies. *BJU Int*. 2013;111:334.
18. Gacci M, et al. Latest Evidence on the Use of Phosphodiesterase Type 5 Inhibitors for the Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia. *Eur Urol*. 2016;70:124.
19. Keating GM, et al. Vardenafil: a review of its use in erectile dysfunction. *Drugs*. 2003;63:2673.
20. Capogrosso P, et al. Time of onset of vardenafil orodispersible tablet in a real-life setting – looking beyond randomized clinical trials. *Expert Rev Clin Pharmacol*. 2017;10:339.
21. Chung E, et al. A state of art review on vardenafil in men with erectile dysfunction and associated underlying diseases. *Expert Opin Pharmacother*. 2011;12:1341.
22. Wang R, et al. Selectivity of avanafil, a PDE5 inhibitor for the treatment of erectile dysfunction: implications for clinical safety and improved tolerability. *J Sex Med*. 2012;9:2122.
23. Goldstein I, et al. A randomized, double-blind, placebo-controlled evaluation of the safety and efficacy of avanafil in subjects with erectile dysfunction. *J Sex Med*. 2012;9:1122.
24. Corona G, et al. The safety and efficacy of Avanafil, a new 2 generation PDE5i: Comprehensive review and meta-analysis. *Expert Opinion on Drug Safety*. 2016;15:237.
25. Zámečník L. Moderní léčba poruch erekce – co víme po dvaceti letech. *Kapitoly z kardiologie pro praktické lékaře*. 2018;10(1):24-27. ISSN 1803-7542.
26. Bittner L. Manažerský dokonalá erekce. *Acta Medicinæ*. 2016;5(11):70. ISSN 1805-398X.
27. Nehra A, et al. Doporučení Princeton III Consensus pro léčbu erektilní dysfunkce a kardiovaskulárních onemocnění. *Mayo Clin Proc*. 2012;87:766.
28. Vlachopoulos C, a kol. Erektlní dysfunkce u kardiovaskulárního pacienta. *Eur Heart J*. 2013;34:2034.
29. Corona G, et al. The use of phosphodiesterase 5 inhibitors with concomitant medications. *J Endocrinol Invest*. 2008;31:799.
30. Porst H, et al. SOP conservative (medical and mechanical) treatment of erectile dysfunction. *J Sex Med*. 2013;10:130.
31. Cai T, et al. The intra-meatal application of alprostadil cream (Vitaros®) improves drug efficacy and patient's satisfaction: results from a randomized, two-administration route, cross-over clinical trial. *Int J Impot Res*. 2019;31:119.
32. Kloner RA. Novel phosphodiesterase type 5 inhibitors: assessing hemodynamic effects and safety parameters. *Clin Cardiol*. 2004;27:120.
33. Padma-Nathan H, et al. An integrated analysis of alprostadil topical cream for the treatment of erectile dysfunction in 1732 patients. *Urology*. 2006;68:386.
34. Shabsigh R, et al. Intracavernous alprostadil alfadex is more efficacious, better tolerated, and preferred over intraurethral alprostadil plus optional actis: a comparative, randomized, crossover, multicenter study. *Urology*. 2000;55:109.
35. Eardley I, et al. Pharmacotherapy for erectile dysfunction. *J Sex Med*. 2010;7:524.
36. Moriel EZ, et al. Sodium bicarbonate alleviates penile pain induced by intracavernous injections for erectile dysfunction. *J Urol*. 1993;149:1299.
37. Duncan C, et al. Erectile dysfunction: a global review of intracavernosal injectables. *World J Urol*. 2019;37:1007.